Clinical Trial Detail

NCT ID NCT04266730
Title Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

head and neck squamous cell carcinoma

lung squamous cell carcinoma

Therapies

PANDA-VAC + Pembrolizumab + Poly ICLC

Age Groups: senior adult

Additional content available in CKB BOOST